FROST PHILLIP MD ET AL 4

What Happened

• Phillip Frost, reported as a 10% owner, acquired 50,000 shares of Cocrystal Pharma, Inc. (COCP) on Feb 6, 2026. The transaction was a purchase (reported as code P) at a weighted average price of $0.95 per share, totaling approximately $47,280. The Form 4 was filed on Feb 9, 2026.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (timely filing).
• Price: weighted average $0.95; individual purchase prices ranged from $0.8899 to $0.9880 (Footnote F1).
• Total shares acquired: 50,000; approximate total value: $47,280.
• Shares held after the transaction: not specified in the information provided in this summary.
• Ownership/structure note (Footnote F2): the shares are held by Frost Gamma Investments Trust (Phillip Frost is trustee); Frost Gamma L.P. is sole beneficiary, with additional layers of entities. Dr. Frost disclaims beneficial ownership of the trust’s securities except to the extent of any pecuniary interest.
• Footnote F3: references inclusion of shares issuable upon vesting of restricted stock units (may affect reported holdings).
• Transaction type: open market or private purchase (the filing lists "open market or private purchase"); purchases are generally considered more informative than routine sales but do not, by themselves, indicate motive.

Context

• This filing reports a direct purchase by a 10% owner via trust-controlled holdings; as a 10% owner (not an unrelated retail insider trade), reporting includes standard ownership disclaimers. No options were exercised, no awards or gifts reported in this transaction.